Webinar Summary
- CRISPR screening as an unbiased approach to identify new targets for hypothesis generation.
- Arrayed format facilitates dissection of complex phenotypes.
- Non-viral delivery of CRISPR/Cas9 reagents such as through nucleofection enables arrayed screening in primary cells.
The MRC-AstraZeneca-University of Cambridge Joint Functional Genomics Screening Laboratory (FGSL) leverages the unique features of arrayed screening, whereby individual genes are edited via CRISPR in plate-based format, to uncover the complexity of developmental and disease signatures using human cellular models. To do this, the laboratory - hosted at the Milner Therapeutics Institute, University of Cambridge - is equipped with a high-throughput screening platform to enable functional endpoint acquisition including high content imaging and flow cytometry.
In this presentation, Dr. Ulrike Künzel and Dr. Chun Hao Wong showcase previous phenotypic screens in complex cell models, in which they overcame some of the inherent challenges in delivering CRISPR/Cas9 reagents, for example, through high throughput nucleofection. They also present routes to form either academic or small/medium-sized enterprise collaborations with the FGSL for arrayed screening.
Presenters
Ulrike Künzel
Ulrike Künzel is an Associate Principal Scientist in the Functional Genomics team at AstraZeneca and co-leading the joint MRC-AstraZeneca-University of Cambridge Functional Genomics Screening Laboratory (FGSL). She has experience in arrayed CRISPR screening for target identification and target validation projects across AstraZeneca’s portfolio. She is a cell biologist by training with an interest in applying CRISPR/Cas9 genome editing in the drug discovery process.
Chun Hao Wong
Chun Hao Wong is a cell biologist specialised in functional genomics and spatial imaging. His research has been highly collaborative, harnessing the strengths of both academia and industry to drive innovation. In the FGSL, he aims to develop and implement high-content screening in a range of collaborative projects to advance mechanistic understanding of development and disease.
Sponsor
Lonza Bioscience
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
